SkyePharma at buy by Jefferies

RBC Capital Markets analyst Robin Campbell rated SkyePharma plc at buy following the company's business review day. The company's new strategy will take at least 12 months to be executed successfully, according to the analyst. Divesting the injectables business would be a positive step. Shares of the London-based pharmaceutical company were down 2 cents, or 0.34%, at $5.80 on volume of 4,685 shares versus the three-month running average of 20,873 shares. (Nasdaq: SKYE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.